BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36576110)

  • 21. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
    Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
    Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.
    Ebid OAEH; Ezz El Arab LR; Saad AS; Ezz El Din M; Mostafa N; Swellam M
    Ann Hematol; 2023 Dec; 102(12):3477-3488. PubMed ID: 37658234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
    Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
    J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
    Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
    [No Abstract]   [Full Text] [Related]  

  • 25. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India.
    Mamgain G; Naithani M; Patra P; Mamgain M; Morang S; Nayak J; Kumar K; Singh S; Bakliwal A; Rajoreya A; Vaniyath S; Chattopadhyay D; Chetia R; Gupta A; Dhingra G; Sundriyal D; Nath UK
    Cureus; 2022 Aug; 14(8):e28241. PubMed ID: 36158348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
    Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
    Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Dobashi A
    J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.
    Kim E; Jiang Y; Xu T; Bazeos A; Knapp A; Bolen CR; Humphrey K; Nielsen TG; Penuel E; Paulson JN
    BMC Cancer; 2022 Mar; 22(1):231. PubMed ID: 35236331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
    Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
    Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
    Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
    Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
    Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?
    Boiza-Sánchez M; Manso R; Balagué O; Chamizo C; Askari E; Salgado RN; Blas-López C; Aguirregoicoa-García E; Menárguez J; Santonja C; Adrados M; Limeres-González MÁ; Piris MÁ; Rodríguez-Pinilla SM
    PLoS One; 2020; 15(11):e0241634. PubMed ID: 33180881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.
    Fan Y; Binshen O; Zhang Z; Yi H; Zhang W; Liu Q; Liu Y; Dong L; Wang C
    Ann Diagn Pathol; 2022 Jun; 58():151886. PubMed ID: 35255429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.